-
Pacira Shares Tumble Following BMO's New Underperform Rating
Wednesday, June 29, 2016 - 4:00pm | 142Read More...BMO analyst Gary Nachman initiated coverage on shares of Pacira Pharmaceuticals Inc (NASDAQ: PCRX) with an Underperform rating and $36 price target Wednesday. Nachman showed concern the Street's current consensus estimate for Exparel sits "too high." Although he called Exparel...
-
4 Reasons To Own Horizon Pharma Shares
Wednesday, June 29, 2016 - 3:54pm | 285Read More...Horizon Pharma plc (NASDAQ: HZNP) shares traded nearly 7 percent higher Wednesday. Investors in the name have responded to a couple news items, a new Outperform rating from BMO analyst Gary Nachman and news of the company's sNDA submission for Ravicti. Nachman set a $29 price target on...
-
BMO Starts Valeant At Market Perform On Debt Burden, Execution Uncertainty
Wednesday, June 29, 2016 - 8:13am | 264Read More...While there is considerable value in some of the key franchises of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its shares have been under pressure, a number of headwinds still lie ahead for the company, BMO Capital Markets’ Gary Nachman said in a report. He assumed coverage of the...
-
Goldman Downgrades Valeant, Sees 'Long Road' For Controversial Stock
Monday, November 2, 2015 - 9:12am | 343Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have declined 47.79 percent over the past month, hitting a low of $90.51 on October 21. Goldman Sachs’ Gary Nachman has downgraded the rating on the company from Buy to Neutral, while lowering the price target from $180 to $122. Nachman...
-
Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel
Wednesday, October 9, 2013 - 11:26am | 140Read More...In a report published Wednesday, Goldman Sachs analyst Gary Nachman reiterated a Neutral rating and $6.80 price target on Amarin Corporation plc (NASDAQ: AMRN). In the report, Goldman Sachs noted, “Given that the upcoming advisory panel for AMRN's Vascepa in the expanded ANCHOR indication on Oct....
-
Leerink Swann Lowers Sucampo Pharmaceuticals (SCMP) Valuation To $6 - $7
Tuesday, March 16, 2010 - 9:05am | 186Read More...Leerink Swann analysts Gary Nachman and Andrew Finkelstein reiterated their Outperform rating for shares of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and lowered valuation of the company's shares to $6 - $7 per share. The analysts said that there were uncertainties in the Sucampo Pharmaceuticals...
-
Valeant Pharmaceuticals International’s (VRX) Fourth-Quarter Review
Tuesday, February 23, 2010 - 9:06pm | 103Read More...Analysts Gary Nachman and Andrew Finkelstein at Leerink Swann have released a report reviewing the fourth-quarter results at Valeant Pharmaceuticals International (NYSE: VRX). The company has reported solid results for the fourth-quarter. The company reported revenue of $241 million for the...
